Combine dengue vaccines to optimize effectiveness.

Abstract Developing a completely effective and safe dengue vaccine has been a complicated process. Dengvaxia®, by Sanofi-Pasteur, and recently TAK003, by Takeda, have strengths and weaknesses, but they seem to complement each other. In this work, we elaborate a rationale that could be applicable in a combined program of these vaccines for the control of dengue.